🔗 Share this article World Health Organization Issues Concern Over Severe Shortage of Obesity Medications Less than 10% of patients eligible to benefit from obesity jabs such as Wegovy have access to them, warns the global health agency as it releases its initial advice on the medications. Considering over a billion individuals worldwide now living with obesity, it is advocating for increased and just availability to this class of drugs. According to forecasts, more than two billion will be living with obesity by 2030 without intervention. "Our latest guidelines affirms that excess weight is a chronic disease that can be treated with holistic and lifelong support," said the agency's head Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and logistical bottlenecks are significant barriers to universal availability to the treatments that can aid individuals in losing significant body mass, notes the body. Weight-Loss Drug Shortage Even in the present most optimistic scenario, the supply of such drugs could only cover approximately 100 million people – fewer than 10% of the global need, according to the health organization. The advice calls on governments and firms to expand availability, through approaches including voluntary licensing. The intellectual property rights on semaglutide – the primary component of the drug Wegovy – is scheduled to end in several countries in 2026. How Obesity Jabs Function These medications mimick a natural hormone to reduce digestion speed, reduce hunger and boost satiety so individuals eat less. Patients typically start to lose weight after several weeks of commencing the weekly injections. Evidence indicates users may regain a significant portion within a year of stopping the drug, as their usual hunger return. Being carrying excess weight increases your chance for contracting health problems, like diabetes, cardiovascular issues, brain attack, and certain malignancies. Excess weight concerns individuals in all nations and was responsible for millions of fatalities worldwide in 2024, according to the WHO.
Less than 10% of patients eligible to benefit from obesity jabs such as Wegovy have access to them, warns the global health agency as it releases its initial advice on the medications. Considering over a billion individuals worldwide now living with obesity, it is advocating for increased and just availability to this class of drugs. According to forecasts, more than two billion will be living with obesity by 2030 without intervention. "Our latest guidelines affirms that excess weight is a chronic disease that can be treated with holistic and lifelong support," said the agency's head Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and logistical bottlenecks are significant barriers to universal availability to the treatments that can aid individuals in losing significant body mass, notes the body. Weight-Loss Drug Shortage Even in the present most optimistic scenario, the supply of such drugs could only cover approximately 100 million people – fewer than 10% of the global need, according to the health organization. The advice calls on governments and firms to expand availability, through approaches including voluntary licensing. The intellectual property rights on semaglutide – the primary component of the drug Wegovy – is scheduled to end in several countries in 2026. How Obesity Jabs Function These medications mimick a natural hormone to reduce digestion speed, reduce hunger and boost satiety so individuals eat less. Patients typically start to lose weight after several weeks of commencing the weekly injections. Evidence indicates users may regain a significant portion within a year of stopping the drug, as their usual hunger return. Being carrying excess weight increases your chance for contracting health problems, like diabetes, cardiovascular issues, brain attack, and certain malignancies. Excess weight concerns individuals in all nations and was responsible for millions of fatalities worldwide in 2024, according to the WHO.